Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Twist Bioscience Sees Q4 Sales $96.000M-$98.000M vs $99.174M Est

Author: Benzinga Newsdesk | August 04, 2025 06:21am

For the fourth quarter, Twist expects: • 

Total revenue of approximately $96 million to $98 million

  • SynBio revenue of approximately $38 million to $39 million
  • NGS revenue of approximately $52 million to $53 million
  • Biopharma revenue of approximately $6 million 

4QFY25 gross margin is projected to be 51% to 52%

Adjusted EBITDA of approximately $(6.0) million to $(8.0) million

Twist expects to achieve adjusted EBITDA breakeven by the end of fiscal 2026

Posted In: TWST


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist